As Managing Partner, Investments, Frédéric is leading adMare’s investments and portfolio companies and brings more than 20 years experience in life sciences investment management.
He has extensive health sciences venture capital expertise through his prior involvement with Desjardins Venture Capital and CDP Capital – Technology Venture (Sofinov) where he was involved in both biopharmaceutical and medical device deals. At Sofinov, he was involved in investments such as NuVasive, Inhibitex, IntraLuminal Therapeutics, Acurian, and TransMedics. While at Desjardins, he showed significant leadership in the creation and management of a profitable early-stage health sciences investment portfolio that included, amongst others, BioAxone Therapeutics, Enobia Pharma, and Tranzyme.
In recent years, Frédéric was involved in project-based investments, as well as developing licensing and spin-off opportunities at MSBi Valorisation (now Aligo Innovation). He has served on the board of directors of many health sciences companies and has been involved on organizing committees of conferences such as MedTech North and AdvaMed.
Frédéric holds an MBA in Finance and International Management from HEC Montréal, a MSc in organic chemistry and a PhD in polymer physical chemistry, both from Université de Montréal.